Limits...
An Increase of Plasma Advanced Oxidation Protein Products Levels Is Associated with Cardiovascular Risk in Incident Peritoneal Dialysis Patients: A Pilot Study.

Gonzalez E, Bajo MA, Carrero JJ, Lindholm B, Grande C, Sánchez-Villanueva R, Del Peso G, Díaz-Almirón M, Iglesias P, Díez JJ, Selgas R - Oxid Med Cell Longev (2015)

Bottom Line: The plasma AOPPs level variation over the first year on PD was significantly associated with CV antecedents and also with CV prognosis.In those patients in whom the AOPPs levels increased more than 50% above the baseline value, a significant association with past and future CV disease was confirmed.These patients had 4.7 times greater risk of suffering later CV disease than those with a smaller increase, even after adjusting for previous CV history.

View Article: PubMed Central - PubMed

Affiliation: Department of Nephrology, Hospital Universitario La Paz, IdiPAZ, Spain.

ABSTRACT
Advanced oxidation protein products (AOPPs) are considered as markers and even mediators of the proinflammatory effect of oxidative stress in uremia. We hypothesized that an increase of oxidative stress associated with peritoneal dialysis (PD), estimated by the variation of plasma AOPPs over time, might be associated with cardiovascular (CV) risk and overall prognosis. In 48 PD patients, blood samples were collected on two occasions: the first one in the first six months after starting PD therapy and the second one, one year after. The plasma AOPPs level variation over the first year on PD was significantly associated with CV antecedents and also with CV prognosis. In those patients in whom the AOPPs levels increased more than 50% above the baseline value, a significant association with past and future CV disease was confirmed. These patients had 4.7 times greater risk of suffering later CV disease than those with a smaller increase, even after adjusting for previous CV history. Our data suggest that the increase of AOPPs plasma level over the first year on PD is conditioned by CV antecedents but also independently predicts CV prognosis. AOPPs plasma levels seem to represent the CV status of PD patients with sufficient sensitivity to identify those with a clearly sustained higher CV risk.

No MeSH data available.


Related in: MedlinePlus

Incidence of new cardiovascular (CV) disease according to changes of plasma AOPPs level during one year on PD. Patients with an increase of AOPP higher than 50% (n = 15) had 4.7 times greater risk of developing a new CV event than those with a smaller increase of AOPP (n = 33). ∗p < 0.001 (significant CV disease in patients with an increase of plasma AOPPs levels greater than 50% versus lower than 50%).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4637127&req=5

fig2: Incidence of new cardiovascular (CV) disease according to changes of plasma AOPPs level during one year on PD. Patients with an increase of AOPP higher than 50% (n = 15) had 4.7 times greater risk of developing a new CV event than those with a smaller increase of AOPP (n = 33). ∗p < 0.001 (significant CV disease in patients with an increase of plasma AOPPs levels greater than 50% versus lower than 50%).

Mentions: The percentage of increase in AOPPs at month 12 was also significantly associated with the development of new CV disease (effect size; phi = 0.612, p < 0.001). Among the patients who developed a CV event, the percentage of patients showing an increase of AOPPs greater than 50% at month 12 was significantly higher than those patients with an increase lower than 50% (64.3% versus 7.7%, p < 0.01). The first group of patients had 4.7 times greater risk (95% CI [2.04, 11.05]) to suffer later CV disease than those with the smaller increase (Figure 2), even after adjustment for prior CV disease history (we first ruled out that the AOPPs levels were a modifier factor between the risk to develop a new CV event in patients with a CV history (Breslow-Day test, p = 0.23) and also that it was a confusion factor (Mantel-Haenszel test, p < 0.05)).


An Increase of Plasma Advanced Oxidation Protein Products Levels Is Associated with Cardiovascular Risk in Incident Peritoneal Dialysis Patients: A Pilot Study.

Gonzalez E, Bajo MA, Carrero JJ, Lindholm B, Grande C, Sánchez-Villanueva R, Del Peso G, Díaz-Almirón M, Iglesias P, Díez JJ, Selgas R - Oxid Med Cell Longev (2015)

Incidence of new cardiovascular (CV) disease according to changes of plasma AOPPs level during one year on PD. Patients with an increase of AOPP higher than 50% (n = 15) had 4.7 times greater risk of developing a new CV event than those with a smaller increase of AOPP (n = 33). ∗p < 0.001 (significant CV disease in patients with an increase of plasma AOPPs levels greater than 50% versus lower than 50%).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4637127&req=5

fig2: Incidence of new cardiovascular (CV) disease according to changes of plasma AOPPs level during one year on PD. Patients with an increase of AOPP higher than 50% (n = 15) had 4.7 times greater risk of developing a new CV event than those with a smaller increase of AOPP (n = 33). ∗p < 0.001 (significant CV disease in patients with an increase of plasma AOPPs levels greater than 50% versus lower than 50%).
Mentions: The percentage of increase in AOPPs at month 12 was also significantly associated with the development of new CV disease (effect size; phi = 0.612, p < 0.001). Among the patients who developed a CV event, the percentage of patients showing an increase of AOPPs greater than 50% at month 12 was significantly higher than those patients with an increase lower than 50% (64.3% versus 7.7%, p < 0.01). The first group of patients had 4.7 times greater risk (95% CI [2.04, 11.05]) to suffer later CV disease than those with the smaller increase (Figure 2), even after adjustment for prior CV disease history (we first ruled out that the AOPPs levels were a modifier factor between the risk to develop a new CV event in patients with a CV history (Breslow-Day test, p = 0.23) and also that it was a confusion factor (Mantel-Haenszel test, p < 0.05)).

Bottom Line: The plasma AOPPs level variation over the first year on PD was significantly associated with CV antecedents and also with CV prognosis.In those patients in whom the AOPPs levels increased more than 50% above the baseline value, a significant association with past and future CV disease was confirmed.These patients had 4.7 times greater risk of suffering later CV disease than those with a smaller increase, even after adjusting for previous CV history.

View Article: PubMed Central - PubMed

Affiliation: Department of Nephrology, Hospital Universitario La Paz, IdiPAZ, Spain.

ABSTRACT
Advanced oxidation protein products (AOPPs) are considered as markers and even mediators of the proinflammatory effect of oxidative stress in uremia. We hypothesized that an increase of oxidative stress associated with peritoneal dialysis (PD), estimated by the variation of plasma AOPPs over time, might be associated with cardiovascular (CV) risk and overall prognosis. In 48 PD patients, blood samples were collected on two occasions: the first one in the first six months after starting PD therapy and the second one, one year after. The plasma AOPPs level variation over the first year on PD was significantly associated with CV antecedents and also with CV prognosis. In those patients in whom the AOPPs levels increased more than 50% above the baseline value, a significant association with past and future CV disease was confirmed. These patients had 4.7 times greater risk of suffering later CV disease than those with a smaller increase, even after adjusting for previous CV history. Our data suggest that the increase of AOPPs plasma level over the first year on PD is conditioned by CV antecedents but also independently predicts CV prognosis. AOPPs plasma levels seem to represent the CV status of PD patients with sufficient sensitivity to identify those with a clearly sustained higher CV risk.

No MeSH data available.


Related in: MedlinePlus